Rameda Pharmaceuticals
Saied Hamdy is an experienced professional in the pharmaceutical and medical analysis fields, currently serving as the Production Associate Unit Head at Rameda Pharmaceuticals since August 2019. In this role, Saied plans and manages production activities while supervising production line operations according to relevant SOPs and safety instructions. Prior to this, Saied worked as a Senior Specialist in the sterile area production at the lyophilizer department, collaborating with the QA team on ISO protocol preparation and successfully establishing the lyophilizer department from inception. Saied began the career at Al Nahar Lab as a Medical Analysis Specialist, performing chemical analyses and reporting on body fluid components, and previously held the position of Shift Manager at Al-Esraa Pharmacy. Saied holds a Diplôme of Analytical Biochemistry and a Bachelor's degree in Chemistry from Minufiya University.
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.